In combination therapy with insulin and DPP-4 inhibitor sitagliptin Study of efficacy and safety

In combination therapy with insulin and DPP-4 inhibitor sitagliptin Study of efficacy and safety - In combination therapy with insulin and DPP-4 inhibitor sitagliptin Study of efficacy and safety

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009908

Enrollment

Registered

2013-01-30

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20 years old or older at the time of obtaining consent Patients who give written consent of their own free will after receiving a sufficient explanation of the study and fully understanding the study before participation.

Exclusion criteria

Exclusion criteria: Medical history of hypersensitivity to sitagliptin Age below 20years old at the time of obtaining consent Judgment of ineligibility to be a subject by the principle investigator

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Secondary

Measure	Time frame
C peptide Glucagon	—

Countries

Japan

Contacts

Public ContactTomoko Nakagami

Tokyo Women's Medical University Diabetes Center

nakagami@dmc.twmu.ac.jp03-3353-8111

Outcome results